Interpace Diagnostics Group (IDXG) Gets a Buy Rating from Oppenheimer

In a report released yesterday, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Interpace Diagnostics Group (IDXGResearch Report), with a price target of $17.00. The company’s shares closed last Monday at $6.79.

According to TipRanks.com, DeGeeter is ranked #2240 out of 5799 analysts.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Interpace Diagnostics Group with a $7.00 average price target, which is a 12.0% upside from current levels. In a report issued on January 7, H.C. Wainwright also reiterated a Buy rating on the stock with a $2.00 price target.

See today’s analyst top recommended stocks >>

Based on Interpace Diagnostics Group’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $7.36 million. In comparison, last year the company had a GAAP net loss of $4.04 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Interpace Biosciences, Inc. operates as an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.